亚洲欧美精品在线-亚洲欧美精品中文字幕在线观看-亚洲欧美精品综合在线观看-亚洲欧美精选-亚洲欧美久久-亚洲欧美久久精品

Hello! Welcome to the official website of Betta Pharmaceuticals!
Service Hotline:+86-571-86130357     Add to Favorites | Online Feedback 中文

 


Bevacizumab (MIL60) is the third drug approved for marketing by Betta Pharmaceuticals and the first approved large molecule biologic.

In February 2017, Betta Pharmaceuticals entered into a collaboration with Beijing MAB Works Biotechnology Co., Ltd. for the bevacizumab injection project, and the entrusted manufacturer is Haizheng Biopharmaceutical Co., Ltd., a subsidiary of Zhejiang Borui Biopharmaceutical Co., Ltd.

In December 2019, the phase III clinical study of bevacizumab injection (MIL60) reached the primary study endpoint. It is a randomized, double-blind, multicenter Phase III study comparing the efficacy and safety of MIL60 in combination with paclitaxel and carboplatin to bevacizumab in combination with paclitaxel and carboplatin for the treatment of subjects with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in primary treatment, led by Professor Wang Jie of Cancer Hospital of Chinese Academy of Medical Sciences with the participation of 50 research centers across China.

In June 2020, MIL60 marketing authorization application was accepted by the State Drug Administration.

In September 2021, MIL60 Phase III clinical research results were presented at the 2021 European Society of Medical Oncology (ESMO) Annual Meeting.

In November 2021, bevacizumab injection (MIL60) was officially approved for marketing, and the approved indications are metastatic colorectal cancer and advanced, metastatic or recurrent non-small cell lung cancer.

In December 2021, the results of bevacizumab research were published in EClinicalMedicine, a subjournal of The Lancet. Four new indications (recurrent glioblastoma; hepatocellular carcinoma; epithelial ovarian, fallopian tube or primary peritoneal carcinoma; and cervical cancer) were accepted for application.

In January 2022, the first order of bevacizumab was dispatched and the first prescriptions were written in several locations across China.

In March 2022, several new indications for bevacizumab (indications for the treatment of patients with recurrent glioblastoma, epithelial ovarian, fallopian tube or primary peritoneal cancer, and cervical cancer) were approved.


 

產品介紹.jpg



 


主站蜘蛛池模板: 国产成人精品久久久久欧美 | 性色av一区二区三区无码 | 麻豆资源| 2024精品久久久久熟女免费网 | 成人精品日本亚洲成熟 | 色婷婷亚洲婷婷六月中文字幕 | 日韩欧国产精品一区综合无码 | 黄色在线网站 | 亚洲精品久久久无码 | 天天干天天插天天射 | 91孕妇精品一区二区三区 | 久久免费视频6 | 亚洲欧美制服中文字幕 | 特级毛片内射WWW无码 | 金瓶梅在线播放 | 免费一级毛片视频 | 国产精品一区二区高潮 | 中文字幕在线无码一区二区三区 | 久久精品久久久66 | 无码动漫性爽xo视频在 | 国内久久久久久久久久 | 亚洲国产91精品在线 | 91久久国产精品 | 青青草在9线观看 | 国产精品玖玖玖在线资源爆乳老 | 亚洲日韩国产色欲影視 | 成人做爰69片免费看网站不忠 | 成人专区欧美亚洲 | 国产亚洲一欧美一区二区三区 | 久久精品无码一区二区无码 | 久精品视频村上里沙 | 亚洲人妻精品一区 | 99久无码中文字幕一本久道 | 色情无码WWW视频无码小说 | 久操视频在线免费观看 | 国产熟女露脸大叫高潮 | 边吃奶边狠狠躁日韩A片 | 欧美日韩一区二区三区 | 国产成a人亚洲精v品无码樱花 | 亚洲香蕉中文网 | 国产精品一区二区69 |